Pam Stetkiewicz
Directeur des opérations chez Arbor Biotechnologies, Inc.
Profil
Pam Stetkiewicz is currently the Director at ImmuneID, Inc. and the Chief Operating Officer at Arbor Biotechnologies, Inc. He has an undergraduate degree from the University of Rhode Island and a doctorate degree from The Johns Hopkins University.
Postes actifs de Pam Stetkiewicz
| Sociétés | Poste | Début |
|---|---|---|
Arbor Biotechnologies, Inc.
 Arbor Biotechnologies, Inc. BiotechnologyHealth Technology Arbor Biotechnologies, Inc. engages in curating genetic biodiversity and discover novel protein functions from nature. The company was founded by David Arthur Svott, Winston Xia Yan, Feng Zhang and David R. Walt in 2016 and is headquartered in Cambridge, MA. | Directeur des opérations | 20/07/2021 |
ImmuneID, Inc.
 ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Directeur/Membre du Conseil | 12/07/2022 |
Formation de Pam Stetkiewicz
| The Johns Hopkins University | Doctorate Degree |
| University of Rhode Island | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Arbor Biotechnologies, Inc.
Arbor Biotechnologies, Inc. BiotechnologyHealth Technology Arbor Biotechnologies, Inc. engages in curating genetic biodiversity and discover novel protein functions from nature. The company was founded by David Arthur Svott, Winston Xia Yan, Feng Zhang and David R. Walt in 2016 and is headquartered in Cambridge, MA. | Health Technology |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Commercial Services |